AUTHORS
Lianxin Zhu, Peng SUN, PhD2, Panpan LIU3, Yan Qin4, Yajun Li5, Guinian Huang6, Hui Li7, Yudan Wu8, Chan Long9, Jihao Zhou10, Xiangjun Fu11, Xiaotao Wang12, Zhiming Li, MD13
AFFILIATIONS
1 Sun Yat-Sen University Cancer Center, Guangzhou, China
2 Sun Yat-Sen University Cancer Center, Guangzhou, China
3 Sun Yat-Sen University Cancer Center, Guangzhou, China
4 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
5 Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
6 Zhongshan Hospital Affiliated to Sun Yat-Sen University, Zhongshan, China
7 Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China
8 Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
9 Huizhou First Hospital, Huizhou, China
10 The Second Clinical Medical College, The First Affiliated Hospital, Shenzhen People's Hospital, Jinan University, Southern University of Science and Technology, Shenzhen, China
11 Hainan General Hospital, Haikou, China
12 Affiliated Hospital of Guilin Medical University, Guilin, China
13 Sun Yat-Sen University Cancer Center, Guangzhou, China
ABSTRACT
Background
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin lymphoma. Glofitamab, a CD20×CD3 bispecific T-cell engager, has demonstrated potent antitumor efficacy and a favorable safety profile in patients with relapsed/refractory DLBCL (R/R DLBCL) across pivotal trials. However, given the restrictive nature of trial eligibility, real-world data on high-risk R/R DLBCL populations are sparse, leaving a critical gap in evidence to inform routine clinical management.
Methods
Eligible patients with high-risk R/R DLBCL (aged ≥ 18 years) treated with and had at least one dose of glofitamab from February 2024 to June 2026 at 10 China centers were enrolled in this multicenter, real-world study. High-risk DLBCL was defined as any of: refractory disease or early relapse, International Prognostic Index (IPI) score 3~5, extranodal involvement, bulky disease, double-hit/triple-hit status, and TP53 mutation, among others. The primary endpoints were best complete response (BCR) rate. Secondary endpoints included best objective response rate (BORR), progression-free survival (PFS) and overall survival (OS), and safety.
Results
This study enrolled 53 patients with high-risk R/R DLBCL. The median age at enrollment was 63 years (range: 26~86 years) and 56.6% of patients were male. Most patients (88.7%) presented with advanced-stage disease (Ann Arbor stage III–IV), 25.6% had bulky disease (≥7.5 cm) and 77.4% had extranodal involvement. Regarding disease risk, 62.3% of patients had a high IPI score (3~5). By cell-of-origin, 36 patients (67.9%) had the non–germinal center B-cell (non-GCB) subtype and 27 patients (32.1%) had the GCB subtype. Molecular profiling revealed that 49.1% of patients were MYC/BCL2 double expressors, and 13.2 harbored double-hit rearrangements (MYC with BCL2). The median number of prior systemic treatment lines was 2 (range, 1~8). A subset of patients had previously undergone autologous hematopoietic stem cell transplantation (7.5%) or CAR-T cell therapy (15.1%) before enrollment.
Patients received a median of 7 cycles of glofitamab treatment (range:2~12). Of these, 33 received glofitamab monotherapy, while the remaining 20 received combination regimens, including glofitamab plus GemOx (n=14) and other agents (n=6). Among all patients enrolled, the observed BORR was 86.8%, including a 50.9% BCR rate. At a median follow-up of 11.2months (range: 1.1~28.4), the median PFS and OS were not reached, with estimated 1-year PFS and OS rates of 67.8% and 86.7%.
Treatment-emergent adverse events (TEAEs) occurred in all patients, with grade ≥3 TEAEs reported in 15.1%. The most common toxicities were cytokine release syndrome (CRS; 39.6%), neutropenia (47.2%), anemia (28.3%), thrombocytopenia (26.4%), and febrile neutropenia (22.6%). Notably, no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) or tumor flare were documented.
Conclusion
This multicenter real-world study indicates that glofitamab-based regimens achieve favorable efficacy with a manageable safety profile in high-risk R/R DLBCL. These findings support the use of glofitamab in routine clinical practice for this challenging population.
DISCLOSURES
Lianxin Zhu: No relevant conflicts of interest to declare.